Page 6 - Read Online
P. 6

Cancer Drug Resistance
               CONTENTS







               Topic: Papers from the BACR Conference-Response and Resistance in
               Cancer Therapy

               1           What really matters - response and resistance in cancer therapy
                            Tim R. Fenton, Michelle D. Garrett, Mark N. Wass, Martin Michaelis
                            Cancer Drug Resist 2018;1:200-203  http://dx.doi.org/10.20517/cdr.2018.19


               2                  Meeting Abstracts of the BACR conference: response and resistance in cancer therapy
                            Tim R. Fenton, Michelle D. Garrett, Martin Michaelis, Mark N. Wass
                            Cancer Drug Resist 2018;1:266-302  http://dx.doi.org/10.20517/cdr.2018.18


               3                    Resistance to ERK1/2 pathway inhibitors; sweet spots, fitness deficits and drug addiction
                            Matthew J. Sale, Kathryn Balmanno, Simon J. Cook
                            Cancer Drug Resist 2019;2:365-380  http://dx.doi.org/10.20517/cdr.2019.14


               4           Glutaminase inhibition in renal cell carcinoma therapy
                            Aleksandra M. Raczka, Paul A. Reynolds
                            Cancer Drug Resist 2019;2:356-364  http://dx.doi.org/10.20517/cdr.2018.004

               5           Targeting MYCN and ALK in resistant and relapsing neuroblastoma
                            Elizabeth R Tucker, Evon Poon, Louis Chesler
                            Cancer Drug Resist 2019;2:803-812  http://dx.doi.org/10.20517/cdr.2019.009


               6           Drug-adapted cancer cell lines as preclinical models of acquired resistance
                            Martin Michaelis, Mark N. Wass, Jindrich Cinatl
                            Cancer Drug Resist 2019;2:447-456  http://dx.doi.org/10.20517/cdr.2019.005
   1   2   3   4   5   6   7   8   9   10   11